DGX
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated historical holders
total: 6
Causeway Capital Management Quest Diagnostics Incorporated transactions over time
- Total transactions:
- 12
- New positions:
- 2
- Sold out:
- 2
- Added:
- 3
- Reduced:
- 5
- Held since:
- 2023 Q2
- Held for:
- 8 quarters
- Latest activity:
- 2025 Q2
Sarah Ketterer has been an institutional investor in Quest Diagnostics Incorporated (DGX) since 2021 Q1. According to 2026 Q1 report, Sarah Ketterer doesn't hold any shares. The fund/company first acquired DGX in 2021 Q1, initially purchasing 319,572 shares. Sarah Ketterer later completely sold out the position and reinvested in DGX again in 2023 Q2. Since the initial investment, Causeway Capital Management has made 11 more transactions in this position.
When did Sarah Ketterer exit their DGX position?
Sarah Ketterer no longer holds Quest Diagnostics Incorporated (DGX). They sold off their entire position in 2025 Q2, closing out an investment that began in 2021 Q1.
When did Sarah Ketterer first invest in DGX?
Sarah Ketterer first invested in Quest Diagnostics Incorporated (DGX) in 2021 Q1 at the reported quarter-end price of $128.34 per share, acquiring 319,572 shares in their initial purchase.
What is Sarah Ketterer's average cost basis for DGX?
Based on historical transaction data, Sarah Ketterer's estimated cost basis for Quest Diagnostics Incorporated (DGX) is approximately $133.66 per share. This represents their average reported price* across all buy transactions.
Has Sarah Ketterer reinvested in DGX after selling?
Yes, Sarah Ketterer has shown renewed interest in Quest Diagnostics Incorporated (DGX). After completely selling their position, they reinitiated an investment in 2023 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $133.66
- Weighted AVG sell price:
- $162.48
DGX transactions history by Causeway Capital Management
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$169.20
|
|
-100% (-120,400)
|
-0.43%
|
|
2025 Q1
|
0.43%
|
120,400
|
$169.20
|
$20,371,692
|
-60.46% (-184,081)
|
-0.71%
|
|
2024 Q4
|
1.05%
|
304,481
|
$150.86
|
$45,934,011
|
-10.99% (-37,579)
|
-0.14%
|
|
2024 Q3
|
1.30%
|
342,060
|
$155.25
|
$53,104,835
|
-28.16% (-134,056)
|
-0.57%
|
|
2024 Q2
|
1.78%
|
476,116
|
$136.88
|
$65,170,798
|
-4.99% (-25,001)
|
-0.09%
|
|
2024 Q1
|
1.75%
|
501,117
|
$133.18
|
$66,737,994
|
+1.71% (+8,410)
|
+0.03%
|
|
2023 Q4
|
1.73%
|
492,707
|
$137.88
|
$67,934,466
|
+0.62% (+3,013)
|
+0.01%
|
|
2023 Q3
|
1.57%
|
489,694
|
$121.86
|
$59,674,164
|
+58.74% (+181,201)
|
+0.58%
|
|
2023 Q2
|
1.14%
|
308,493
|
$140.56
|
$43,361,828
|
new
|
+1.14%
|
|
2021 Q3
|
0.00%
|
0
|
$131.97
|
|
-100% (-305,502)
|
-0.82%
|
|
2021 Q2
|
0.82%
|
$131.97
|
-4.40% (-14,070)
|
|||
|
2021 Q1
|
0.81%
|
$128.34
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.